Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis

(2014) Yahiya Y. Syed et al.   DRUGS

Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience

(2014) Jürgen Koehler   EUROPEAN NEUROLOGY

Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice

(2014) Peter Flachenecker et al.   EUROPEAN NEUROLOGY

A Biophysical Model of Endocannabinoid-Mediated Short Term Depression in Hippocampal Inhibition

(2013) Margarita Zachariou et al.   PLoS One

Short interval intracortical facilitation correlates with the degree of disability in multiple sclerosis

(2012) Francesco Mori et al.   Brain Stimulation

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

Cannabis-based treatment induces polarity-reversing plasticity assessed by theta burst stimulation in humans

(2009) Giacomo Koch et al.   Brain Stimulation

Intracortical excitability in patients with relapsing–remitting and secondary progressive multiple sclerosis

(2009) A. Conte et al.   JOURNAL OF NEUROLOGY

Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis

(2009) Diego Centonze et al.   NEUROLOGICAL SCIENCES